Oak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an Angelman syndrome medicine.
Merger will help Oak Hill Bio revive old Roche drug for Angelman syndrome
An image of the chromosomes of someone with Angelman syndrome, a genetic disorder caused by a lack of function of part of chromosome 15Adobe
By Jason MastJuly 27, 2026
General Assignment Reporter
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
The trend continues in which big-name venture investors band together to back new companies with an experimental medicine…
It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before…
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly…
Lyora Therapeutics launches with $2.5M in pre-seed funding to revive stalled eye gene therapy programs from Editas and Biogen,…
Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an…
Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing…
